PASG · Passage BIO, Inc.
$4.52
-0.05 (-1.09%)
At close · Jul 29
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed May 12, 2026
Market Cap
$14.50M
Shares
3.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.52
Open$4.50
Day$4.41–4.64
52W$3.29–20.00
Avg vol 30d117K
Short int125K · 3.9% float · 2.6d
Short vol84%
Last earningsMay 13, 2025
DataFeb 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
−13%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−57%
trailing
YTD return
−62%
this year
Relative strength
−65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Distributing
5 of 35 funds reported for Jun 30 · net -29.6K sh shares · +1 new
Insider flow
Accumulating
Net +$206.1K over 90 days · 0% sells
Short interest
Rising
3.89% of float · ▲ +9.1% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 1-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
EPS growth
+32%
Y/Y
Balance sheet
$46.3M
net cash
Quant / Vol
risk profile
Volatility
115%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Distributing
5 of 35 funds reported for Jun 30 · net -29.6K sh shares · +1 new
Insider flow
Accumulating
Net +$206.1K over 90 days · 0% sells
Short interest
Rising
3.89% of float · ▲ +9.1% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $5 · 7%
52-wk high $20
vs 200-day avg -44%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PASG
this stock
Passage BIO, Inc.
|
$14.50M | -61.7% | — | — | 3.9% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PASG | -8.1% | -7.4% | -57.2% | -7.4% | -61.7% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -7.1% | -7.4% | -64.7% | -6.6% | -70.3% |